Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 4

2(33.3%)

Phase 1

1(16.7%)

6Total

Phase 2(3)

Phase 4(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04562129Phase 2Recruiting

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Role: collaborator

NCT05547321Phase 1Recruiting

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

Role: collaborator

NCT01856023Phase 4Terminated

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

Role: lead

NCT04908748Phase 2Completed

Efficacy and Safety of Esflurbiprofen Hydrogel Patch in the Treatment of Local Acute Pain

Role: collaborator

NCT03501381Phase 2Active Not Recruiting

High Dose IL 2 and Entinostat in RCC

Role: collaborator

NCT04960891Unknown

A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp

Role: collaborator

NCT04530994Unknown

A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)

Role: collaborator

NCT04750057Unknown

Anifrolumab Early Access Program

Role: collaborator

NCT01683188Phase 4Terminated

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Role: lead

All 9 trials loaded